Difficult-to-treat gouty arthritis: A disease warranting better management

Drugs

Volumn 71, Issue 11, 2011, Pages 1413-1439

  Schlesinger, Naomi ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Allopurinol; BCX 4208; Canakinumab; Colchicine; Corticosteroids; Febuxostat; Gouty arthritis; Lesinurad; Nonsteroidal anti inflammatories; Pegadricase; Pegloticase; Quality of life; Rilonacept; Tranilast; Uricosurics.

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; BCX 4208; BENZBROMARONE; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; ETORICOXIB; FEBUXOSTAT; INDOMETACIN; INTERLEUKIN 1BETA; LESINURAD; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEGADRICASE; PEGLOTICASE; PREDNISOLONE; PROBENECID; RDEA 594; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SULFINPYRAZONE; TRANILAST; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; URATE; URICOSURIC AGENT;

ABSENCE OF SIDE EFFECTS; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMORBIDITY; CORONARY ARTERY DISEASE; COST OF ILLNESS; DIABETES MELLITUS; DIALYSIS; DIARRHEA; DRESS SYNDROME; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GOUT; HEADACHE; HEALTH CARE COST; HEALTH INSURANCE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION COST; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERURICEMIA; INFECTION; INJECTION SITE ERYTHEMA; JOINT STIFFNESS; KIDNEY DISEASE; KIDNEY FAILURE; LOW DRUG DOSE; LYMPHOCYTE SUBPOPULATION; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; NONHUMAN; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL;

EID: 79961132862     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11592290-000000000-00000     Document Type: Review

References (125)

1. Schlesinger N. Diagnosis of gout. Minerva Med 2007; 98 (6): 759-67. (Pubitemid 351196064)
2. Schlesinger N. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am JManag Care 2005; 11 Suppl. 15: 443-50; quiz 465-8.
3. Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med 2008; 75 Suppl. 5: 5-8.
4. Dalbeth N, Clark B, Gregory K, et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis 2009; 68 (8): 1290-5.
5. Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 2010; 69 (11): 1907-12.
6. Zhu Y, Pandya B, Choi H. Increasing gout prevalence in the US over the last two decades: the national health and nutrition examination survey (NHANES). 74th Annual Scientific Meeting of the American College of Rheumatology, 2010 Nov 7-11; Atlanta (GA).
7. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002; 40 (1): 37-42. (Pubitemid 34701209)
8. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31 (8): 1582-7. (Pubitemid 39006641)
9. Zeng Q, Wang Q, Chen R, et al. Primary gout in Shantou: a clinical and epidemiological study. Chin Med J (Engl) 2003; 116 (1): 66-9. (Pubitemid 36432725)
10. Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995; 48 (9): 1153-8.
11. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004; 50 (8): 2400-14. (Pubitemid 39066263)
12. Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10 (6): 308-14. (Pubitemid 39614246)
13. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006; 81 (7): 925-34. (Pubitemid 43993484)
14. Wu EQ, Patel PA, Yu AP, et al. Disease-related and allcause health care costs of elderly patients with gout. J Manag Care Pharm 2008; 14 (2): 164-75. (Pubitemid 351453817)
15. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009; 11 (2): R46.
16. Halpern R, Mody RR, Fuldeore MJ, et al. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009; 25 (7): 1711-9.
17. Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009; 48 (5): 582-6.
18. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64 (2): 267-72. (Pubitemid 40197509)
19. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford) 2007; 46 (9): 1441-4. (Pubitemid 47317091)
20. Roddy E, Mallen CD, Hider SL, et al. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford) 2010; 49 (1): 105-11.
21. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann RheumDis 2008; 67 (7): 960-6. (Pubitemid 351956658)
22. Perez-Ruiz F, Martinez-Indart L, Carmona L, et al. Severity of gout and mortality [abstract]. Arthritis Rheum 2009; 60 Suppl. 10: 1946.
23. Koh WH, Seah A, Chai P. Clinical presentation and disease associations of gout: a hospital-based study of 100 patients in Singapore. Ann Acad Med Singapore 1998; 27 (1): 7-10.
24. Yood RA, Baraf HSB, Becker MA, et al. Clinical manifestations of treatment failure gout (TFG) in four independent cohorts [abstract]. Ann Rheum Dis 2009; 68 Suppl. 3: 323.
25. Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009; 36 (5): 1041-8.
26. Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 1997; 50 (8): 953-9. (Pubitemid 27423526)
27. Scott JT, Higgens CS. Diuretic induced gout: a multifactorial condition. Ann Rheum Dis 1992; 51 (2): 259-61.
28. Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57 (1): 109-15.
29. Rho YH, Choi SJ, Lee YH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005; 20 (6): 1029-33.
30. Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19 (12): 2407-13.
31. Rocca Rey LA. Prevalence and costs of gout in patients with chronic kidney disease in a privately insured population [abstract]. Arthritis Rheum 2007; 56 Suppl. 9: 89.
32. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008; 67 (9): 1310-6.
33. Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004; 63 (6): 723-9. (Pubitemid 38658404)
34. Khanna D, Ahmed M, Yontz D, et al. The disutility of chronic gout. Qual Life Res 2008; 17 (5): 815-22.
35. Khanna P, Perex-Ruiz F, Maranian P, et al. Uratelowering therapy results in clinically important improvements in health-related quality of life-analysis from an academic clinical practice [abstract]. Ann Rheum Dis 2010; 69 Suppl. 3: 717.
36. Strand V, Edwards L, Singh JA.Health-related quality-of-life (HRQOL) of patients with treatment failure gout (TFG) is poor, and comparable to that in other severe chronic conditions [abstract]. Ann Rheum Dis 2009; 68 Suppl. 3: 168.
37. Strand V, Edwards NL, Baraf HSB, et al. Improvement in health-related quality of life (HRQOL) in patients with treatment failure gout (TFG) treated with pegloticase measured by SF-6D derived utility [abstract]. Arthritis Rheum 2009; 60 Suppl. 10: 1101.
38. Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 2011; 13 (2): R53.
39. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2007; 13 Suppl. 9: 237-51.
40. Strand V, Petri M, Buyon J, et al. Systemic lupus erythematosus (SLE) impacts all domains of health-related quality of life (HRQOL): baseline results from five randomized controlled trials (RCTs) [abstract]. Ann Rheum Dis 2007; 66 Suppl. 2: 482.
41. Martin M, Blaisdell-Gross B, Fortin EW, et al. Healthrelated quality of life of heart failure and coronary artery disease patients improved during participation in disease management programs: a longitudinal observational study. Dis Manag 2007; 10 (3): 164-78. (Pubitemid 47400547)
42. Piotrowicz K, Noyes K, Lyness JM, et al. Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial II. Eur Heart J 2007; 28 (5): 601-7. (Pubitemid 47355502)
43. Alvarez-Hernandez E, Pelaez-Ballestas I, Vazquez-Mellado J, et al. Validation of the Health Assessment Questionnaire disability index in patients with gout. Arthritis Rheum 2008; 59 (5): 665-9. (Pubitemid 351679541)
44. Alvarez-Nemegyei J, Cen-Piste JC, Medina-Escobedo M, et al. Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout. J Rheumatol 2005; 32 (10): 1923-7. (Pubitemid 41430484)
45. So A, De Meulemeester M, Pikhlak A, et al. Rapid improvement in health-related quality of life (HRQoL) in gouty arthritis patients treated with canakinumab (ACZ885) compared to triamcinolone acetonide. 74th Annual Scientific Meeting of the American College of Rheumatology, 2010 Nov 7-11; Atlanta (GA).
46. Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health 2007; 10 (4): 231-7. (Pubitemid 47077244)
47. Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum 2008; 58 (9): 2587-90.
48. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin 2006; 22 (7): 1381-9. (Pubitemid 44085590)
49. Hanly JG, Skedgel C, Sketris I, et al. Gout in the elderly: a population health study. J Rheumatol 2009; 36 (4): 822-30.
50. Wu EQ, Yu AP, Guerin A, et al. The costs of treatment failure gout: a claims-based analysis [abstract]. Arthritis Rheum 2009; 60 Suppl. 10: 1112.
51. Wu EQ, Patel PA,ModyRR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 2009; 36 (5): 1032-40.
52. Halpern R, FuldeoreMJ,Mody RR, et al. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009; 15 (1): 3-7.
53. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout: part II, management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). AnnRheumDis 2006; 65 (10): 1312-24. (Pubitemid 44620440)
54. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51 (3): 321-5. (Pubitemid 38725128)
55. Yamanaka H, Togashi R, HakodaM, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998; 431: 13-8. (Pubitemid 28236731)
56. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004; 64 (21): 2399-416. (Pubitemid 39480701)
57. Schlesinger N, Moore DF, Sun JD, et al. A survey of current evaluation and treatment of gout. J Rheumatol 2006; 33 (10): 2050-2. (Pubitemid 44571881)
58. Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol 2007; 34 (7): 1566-8. (Pubitemid 47067996)
59. Gnanenthiran SR, Hassett GM, Gibson KA, et al. Acute gout management during hospitalisation: a need for a protocol. Intern Med J. Epub 2010 Jan 4.
60. Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50 (2): 598-606. (Pubitemid 38202232)
61. Schumacher Jr HR, Boice JA,Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.BMJ 2002; 324 (7352): 1488-92. (Pubitemid 34666615)
62. Pascual E, Sivera F. Therapeutic advances in gout. Curr Opin Rheumatol 2007; 19 (2): 122-7. (Pubitemid 46208769)
63. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347 (26): 2104-10. (Pubitemid 36015122)
64. American Geriatric Society. Panel on the pharmacological mangement of persistent pain in older persons. J Am Geriatr Soci 2009; 57: 1331-46.
65. Hoskison KT, Wortmann RL. Management of gout in older adults: barriers to optimal control. Drugs Aging 2007; 24 (1): 21-36. (Pubitemid 46148079)
66. Kelly W, Wortmann RL. Crystal-associated synovitis: gout and hyperuricemia. Philadelphia (PA): Saunders, 1993.
67. Katzung BG. Nonsteroidal anti-inflammatory drugs; nonopioid analgesics; drugs used in gout. In: Katzung BG, editor. Basic and clinical pharmacology. Norwalk: Apleton and Lange, 1995: 536-59.
68. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440 (7081): 237-41. (Pubitemid 43372104)
69. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallelgroup, dose-comparison colchicine study. Arthritis Rheum 2010; 62 (4): 1060-8.
70. Colcrys (Colchicine) [package insert]. Philadelphia (PA): AR Scientific Inc, 2009.
71. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31 (12): 2429-32. (Pubitemid 39610535)
72. Paulus HE, Schlosstein LH, Godfrey RG, et al. Prophylactic colchicine therapy of intercritical gout: a placebocontrolled study of probenecid-treated patients. Arthritis Rheum 1974; 17 (5): 609-14.
73. Janssens HJ, Lucassen PL, Van de Laar FA, et al. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008; (2): CD005521.
74. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371 (9627): 1854-60. (Pubitemid 351736009)
75. Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20 (1): 111-3. (Pubitemid 23049192)
76. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994; 21 (7): 1325-7. (Pubitemid 24234673)
77. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for treatment of acute flares in refractory gouty arthritis. Arthritis Rheum 2010; 62 (10): 3064-74.
78. Fernandez C, Noguera R, Gonzalez JA, et al. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26 (10): 2285-6. (Pubitemid 29487039)
79. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009; 48 Suppl. 2: ii9-14.
80. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007; 57 (7): 1324-8. (Pubitemid 47585481)
81. Becker MA, Schumacher Jr HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353 (23): 2450-61. (Pubitemid 41781828)
82. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12 (2): R63.
83. Schumacher Jr HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum2008; 59 (11): 1540-8.
84. Zyloprim (Allopurinol) [package insert]. San Diego (CA): Prometheus Laboratories Inc, 2003.
85. Allopurinol: summary of product characteristics. South Ruislip, UK: Milpharm Ltd, 2009.
86. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007; 66 (10): 1311-5. (Pubitemid 47492473)
87. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58 (1): 25-32. (Pubitemid 350298142)
88. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004; 31 (8): 1575-81. (Pubitemid 39006640)
89. Komoriya K, Hoshide S, Takeda K, et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 2004; 23 (8-9): 1119-22. (Pubitemid 39625879)
90. ULORIC (Febuxostat) [package insert]. North Deerfield (IL): Takeda Pharmaceuticals America, 2009.
91. Perez-Ruiz F. Risk factors for renal lithiasis during treatment with uricosuric drugs [abstract]. Arthitis Rheum 2009; 60 (10): 1499.
92. Schlesinger N, Yasothan U, Kirkpatrick P. Pegloticase. Nat Rev Drug Discov 2011; 10 (1): 17-8.
93. Varela-Echavarria A, Montes de Oca-Luna R, Barrera-Saldana HA. Uricase protein sequences: conserved during vertebrate evolution but absent in humans. Faseb J 1988; 2 (15): 3092-6.
94. Maroli AN, Waltrip R, AltonM, et al. First application of computer-assisted analysis of digital photographs for assessing tophus response: phase 3 studies of pegloticase in treatment failure gout [abstract]. Arthritis Rheum 2009; 60 Suppl. 10: 1111.
95. Sundy JS, Baraf HSB, Becker MA, et al. Efficacy and safety of intravenous pegloticase (PGL) in treatment failure gout (TFG): results from GOUT1 and GOUT2 [abstract]. Ann Rheum Dis 2009; 68 Suppl. 3: 318.
96. Savient Pharmaceuticals Ltd. KrystexxaTM (pegloticase): prescribing information [online]. Available from URL: www.krystexxa.com/pdfs/ KRYSTEXXAPrescribing-Infor mation.pdf [Accessed 2011 Jun 27].
97. Anderson A, Singh JA. Pegloticase for chronic gout. Cochrane Database Syst Rev 2010; 3: CD008335.
98. WrightD, Sundy JS, Rosario-Jansen T. Routine serum uric acid (SUA) monitoring predicts antibody-mediated loss of response and infusion reaction risk during pegloticase therapy [abstract]. Arthritis Rheum 2009; 60 Suppl. 10: 1104.
99. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9 (2): R28.
100. Cho M, Ghosh P, Hans G, et al. The safety and efficacy of Anakinra in the treatment of acute gout in hospitalized patients [abstract]. Arthritis Rheum 2010; 60 Suppl. 9: 163.
101. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 68 (10): 1613-7.
102. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011; 70 (7): 1264-71.
103. Schumacher RH, Sundy JS, Terkeltaub R, et al. Placebocontrolled study of rilonacept for prevention of gout flares during initiation of urate-lowering therapy [abstract]. Ann Rheum Dis 2009; 68 Suppl. 3: 680.
104. Perez-Ruiz F, Hingorani V, Welp J, et al. Efficacy and safety of a range of doses of RDEA594, a novel uricosuric agent, as a single agent in hyperuricemic gout patients: multicenter, randomized, double-blind, placebo-controlled, phase 2 experience [abstract]. Ann Rheum Dis 2010; 69 Suppl. 3: 121.
105. Sundy JS, Kitt M. Tranilast, a novel, potential treatment for the chronic management of hyperuricemia in patients with gout, reduces serum uric acid (SUA) in healthy subjects [abstract]. Ann Rheum Dis 2010; 69 Suppl. 3: 607.
106. Fitz-Patrick D, Drummond W, Pappas J, et al. Effects of a purine nucleoside phosphorylase inhibitor, BCX4208, on the serum uric acid concentrations in patients with gout. 74th Annual Scientific Meeting of the American College of Rheumatology, 2010 Nov 7-11; Atlanta (GA).
107. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 2008; 4 (1): 34-42.
108. So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008; 10 (5): 221.
109. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201 (9): 1355-9. (Pubitemid 40664079)
110. Tunyogi-Csapo M, Kis-Toth K, Radacs M, et al. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblastmediated pathologic bone resorption. Arthritis Rheum 2008; 58 (8): 2397-408.
111. Kim JH, Jin HM, Kim K, et al. The mechanism of osteoclast differentiation induced by IL-1. J Immunol 2009; 183 (3): 1862-70.
112. Burger D, Dayer JM, Palmer G, et al. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006; 20 (5): 879-96. (Pubitemid 44382385)
113. Kapur S, Bonk ME. Rilonacept (Arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. Pharm Ther 2009; 34 (3): 138-41.
114. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10 (3): R67.
115. Terkeltaub R, Sundy JS, Schumacher HR, et al. The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study. Ann Rheum Dis 2009; 68 (10): 1613-7.
116. Neogi T. IL-1 antagonism in acute gout: is targeting a single cytokine the answer? Arthritis Rheum 2010; 62 (10): 2845-9.
117. Bomalaski JS, Clark MA. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 2004; 6 (3): 240-7.
118. Bomalaski JS, Holtsberg FW, Ensor CM, et al. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002; 29 (9): 1942-9. (Pubitemid 34988704)
119. DalbethN, SoA.Hyperuricaemia and gout: state of the art and future perspectives. Ann Rheum Dis 2010; 69 (10): 1738-43.
120. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417 (6887): 447-52. (Pubitemid 34563537)
121. Ardea Biosciences, Inc. Allopurinol combination study (RDEA594-203) [ClinicalTrials.gov identifierNCT01001338]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 27].
122. Mandal A, Emerling D, Serafini T, et al. Tranilast inhibits urate transport mediated by URAT1 and GLUT9. 74th Annual Scientific Meeting of the American College of Rheumatology, 2010 Nov 7-11; Atlanta (GA).
123. Serafini TA, Emerling DE. Tranilast suppresses inflammation induced by monosodium urate (MSU) crystals in vivo [abstract]. Ann Rheum Dis 2010; 69 Suppl. 3: 664.
124. Nuon Therapeutics, Inc. Tranilast plus allopurinol in patients with moderate to severe gout (TAnGO) [Clinical-Trials.gov identifierNCT01109121]. USNational Institutes of Health, ClinicalTrials.gov [online]. Available fromURL: http://www.clinicaltrials.gov [Accessed 2011 Jun 27].
125. BioCryst Pharmaceuticals. Study to evaluate sUA-lowering activity, safety and PK interaction of oral BCX4208 and allopurinol administration in subjects with gout [Clinical-Trials.gov identifierNCT01129648].USNational Institutes of Health, ClinicalTrials.gov [online]. Available fromURL: http://www. clinicaltrials.gov [Accessed 2011 Jun 27]